From: Integration of molecular features with clinical information for predicting outcomes for neuroblastoma patients
Stage 1
(n = 10)
Stage 2
(n = 21)
Stage 3
(n = 33)
Stage 4 s
(n = 16)
Stage 4
(n = 159)
Group 1
0%
37.5%
47%
Group 2
60%
52%
100%
6%
Group 3
30%
37%
Group 4
48%
Group 5
10%
13%
16%